Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review

Leukemia Research

Volumn 36, Issue 1, 2012, Pages 81-86

  Rauh, Michael J ^a   Rahman, Fazlur ^b   Good, David ^c   Silverman, Jeffrey ^d   Brennan, Michael K ^d   Dimov, Nikolay ^e   Liesveld, Jane ^f   Ryan, Daniel H ^f   Richard Burack, W ^f   Bennett, John M ^f  

^a QUEEN S UNIVERSITY   (Canada)

^b West Texas Medical Associates   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d NORTH YORK GENERAL HOSPITAL   (Canada)

^e Bioreference Laboratory   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cutaneous; Dendritic; Leukemia; Leukemic; Neoplasm; Plasmacytoid

Indexed keywords

ALEMTUZUMAB; CD2 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HLA DR ANTIGEN; HYDROXYUREA; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL TUMOR; BONE MARROW EXAMINATION; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CASE REPORT; CHROMOSOME ADDITION; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; HEPATOSPLENOMEGALY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; KIDNEY FAILURE; LABORATORY TEST; LEUKEMIC BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; LEUKOCYTOSIS; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; NORMOCHROMIC NORMOCYTIC ANEMIA; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTOPENIA; WEIGHT REDUCTION;

DENDRITIC CELLS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 83555164837     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.033     Document Type: Article

References (21)

1. Chaperot L., Bendriss N., Manches O., Gressin R., Maynadie M., Trimoreau F., et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001, 97(10):3210-3217.
2. Feuillard J., Jacob M.C., Valensi F., Maynadié M., Gressin R., Chaperot L., et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002, 99(5):1556-1563.
3. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer (IARC), Lyon. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
4. Cota C., Vale E., Viana I., Requena L., Ferrara G., Anemona L., et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010, 34(1):75-87.
5. Li Y., Li Z., Lin H.L., Chen X.H., Li B. Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature. Pathol Res Pract 2010, 207(1):55-59.
6. Jegalian A.G., Facchetti F., Jaffe E.S. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 2009, 16(6):392-404.
7. Comeau M.R., Van der Vuurst de Vries A.R., Maliszewski C.R., Galibert L. CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion?. J Immunol 2002, 169(1):75-83.
8. Matsui T., Connolly J.E., Michnevitz M., Chaussabel D., Yu C.I., Glaser C., et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009, 182(11):6815-6823.
9. Leroux D., Mugneret F., Callanan M., Radford-Weiss I., Dastugue N., Feuillard J., et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood 2002, 99(11):4154-4159.
10. Dijkman R., van Doorn R., Szuhai K., Willemze R., Vermeer M.H., Tensen C.P. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007, 109(4):1720-1727.
11. Jardin F., Callanan M., Penther D., Ruminy P., Troussard X., Kerckaert J.P., et al. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia 2009, 23(4):698-707.
12. Wiesner T., Obenauf A.C., Cota C., Fried I., Speicher M.R., Cerroni L. Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol 2010, 130(4):1152-1157.
13. Garnache-Ottou F., Feuillard J., Ferrand C., Biichle S., Trimoreau F., Seilles E., et al. GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 2009, 145(5):624-636.
14. Herling M., Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007, 127(5):687-700.
15. Petrella T., Bagot M., Willemze R., Beylot-Barry M., Vergier B., Delaunay M., et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005, 123(5):662-675.
16. Ham M.F., Ko Y.-H. Natural killer cell neoplasm: biology and pathology. Int J Hematol 2010, 92:681-689.
17. Dietrich S., Andrulis M., Hegenbart U., Schmitt T., Bellos F., Martens U.M., et al. Blastic plasmacytoid dendritic cell neoplasia in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant 2011, 17(8):1250-1254.
18. Tsagarakis N.J., Kentrou N.A., Papadimitriou K.A., Pagoni M., Kokkini G., Papadaki H., et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010, 34(4):438-446.
19. Reichard K.K., Burks E.J., Foucar M.K., Wilson C.S., Viswanatha D.S., Hozier J.C., et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005, 29(10):1274-1283.
20. Reineks E.Z., Osei E.S., Rosenberg A., Auletta J., Meyerson H.J. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom 2009, 76(4):237-248.
21. Reimer P., Rüdiger T., Kraemer D., Kunzmann V., Weissinger F., Zettl A., et al. What is CD4+CD56+ malignancy and how should it be treated?. Bone Marrow Transplant 2003, 32(7):637-646.